Przejdź do zawartości
Merck

Y0001062

Losartan potassium

European Pharmacopoeia (EP) Reference Standard

Synonim(y):

2-Butyl-4-chloro-1-{[2′-(1H-tetrazol-5-yl)(1,1′-biphenyl)-4-yl]methyl}-1H-imidazole-5-methanol monopotassium salt, 2-butyl-4-chloro-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]- 1H-Imidazole-5-methanol potassium salt, DuP 753, MK 954, Potassium 5-(4′-((2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl)methyl)-[1,1′-biphenyl]-2-yl)tetrazol-1-ide

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Wzór empiryczny (zapis Hilla):
C22H22ClKN6O
Numer CAS:
Masa cząsteczkowa:
461.00
Beilstein:
5845770
Numer MDL:
Kod UNSPSC:
41116107
Identyfikator substancji w PubChem:
NACRES:
NA.24

klasa czystości

pharmaceutical primary standard

rodzina API

losartan

producent / nazwa handlowa

EDQM

Zastosowanie

pharmaceutical (small molecule)

Format

neat

ciąg SMILES

CCCCc1nc(Cl)c(CO)n1Cc2ccc(cc2)-c3ccccc3-c4nnnn4[K]

InChI

1S/C22H22ClN6O.K/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22;/h4-7,9-12,30H,2-3,8,13-14H2,1H3;/q-1;+1

Klucz InChI

OXCMYAYHXIHQOA-UHFFFAOYSA-N

informacje o genach

human ... AGTR1(185)

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Opis ogólny

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Zastosowanie

Losartan potas EP Wzorzec odniesienia, przeznaczony do stosowania w badaniach laboratoryjnych wyłącznie zgodnie z zaleceniami Farmakopei Europejskiej.

Działania biochem./fizjol.

Losartan potassium is an orally available, potent, and selective competitive angiotensin II receptor type 1 (AT1) antagonist. Losartan potassium is used for treatment of hypertension.
orally available, potent, and selective competitive angiotensin II receptor type 1 (AT1) antagonist

Opakowanie

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Inne uwagi

Sales restrictions may apply.
Ta strona może zawierać tekst przetłumaczony maszynowo.

Kod klasy składowania

11 - Combustible Solids

Klasa zagrożenia wodnego (WGK)

WGK 3

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable


Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumenty section.

Proszę o kontakt, jeśli potrzebna jest pomoc Obsługa Klienta

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Klienci oglądali również te produkty

Satoshi Terada et al.
The Journal of bone and joint surgery. American volume, 95(11), 980-988 (2013-06-20)
Muscle contusions are a common type of muscle injury and are frequently encountered in athletes and military personnel. Although these injuries are capable of healing in most instances, incomplete functional recovery often occurs because of the development of fibrosis in
Christiane Pees et al.
The American journal of cardiology, 112(9), 1477-1483 (2013-07-23)
Since 2008, when angiotensin II type I receptor blockade with losartan was introduced in the prevention of cardiovascular manifestation of Marfan syndrome (MFS), a specific treatment to address the cardiovascular lesions became available. The present study aimed to compare the
K L Goa et al.
Drugs, 51(5), 820-845 (1996-05-01)
Losartan potassium is an orally active, nonpeptide angiotensin II (AII) receptor antagonist. It is the first of a new class of drugs to be introduced for clinical use in hypertension. This novel agent binds competitively and selectively to the AII
M Burnier et al.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 13(1), S23-S28 (1995-07-01)
The evaluation of a new drug in normotensive volunteers provides important pharmacodynamic and pharmacokinetic information as long as the compound has a specific mechanism of action which can be evaluated in healthy subjects as well as in patients. The purpose
L M Burrell
Drug safety, 16(1), 56-65 (1997-01-01)
Losartan potassium is the first of a new class of orally active antihypertensive drugs which antagonise the action of angiotensin (AT) II at the AT1 receptor subtype. Losartan potassium is converted by the liver to the active metabolite E-3174, which

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej